Clinical Trial Management Solution Now Offers a Robust and Intuitive System with Real-time Information to Organize a Trial
Radiant Sage LLC, a provider of on-demand clinical trial imaging infrastructure solutions, today announced the release of its Clinical Trial Management System (CTMS), RadClinica™ version 3.0. This single, centralized system adds to the Corelab-In-A-Box platform (see recent release for version 3.1) by providing a set of features to manage the execution of multiple imaging studies with real-time access in a cloud-based platform.
"Today it is very common that key stakeholders in a clinical trial are located around the globe, making communication, collaboration and management a challenge," said Jesse Bowden, COO of Radiant Sage. "However, with cloud-based applications, like our RadClinica CTMS, all users have real-time access to the information as data is collected, processed and managed."
RadClinica has been specifically designed to orchestrate operational, training and administrative activities of multiple imaging clinical trials. It is integrated with Radiant Sage's other imaging products to provide a comprehensive software suite. Version 3.0 offers the following new features and functionality:
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.